• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

    3.160 -0.060 (-1.86%)
    Streaming Delayed Price Updated: 11:03 AM EST, Jan 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Cellectar Biosciences, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
    Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
    CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
    CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
    CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall Survival 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
    Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
    Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
    Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Patients 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
    In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median 
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Synergy CHC Corp. (NASDAQ: SNYR) Restructures Debt with $20M Facility to Power Global Growth and FOCUSfactor Beverage Expansion
    Via AB Newswire
    News headline image
    Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Announces Plan to Explore Strategic Alternatives
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Present at the 37th Annual Roth Conference
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.